clinical trial · NCT05376579
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Active Secondary Progressive Multiple Sclerosissiponimod
brief summary
This is an observational, multicenter, single-arm, prospective study conducted in Italy
started
Jun 17, 2022
primary completion
Jul 22, 2025
completion
Jul 22, 2025
last updated
Dec 18, 2025
detailed description
Primary data will be collected over a period of three years. Medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of the effects of siponimod treatment on an individual basis.
official title
Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol